In the biopharmaceutical field, cell filling equipment serves ascore production equipment in Class A clean areas, its import involvesMedical Equipmentregistration certificates, biosafety certifications, GMP compliance declarationsa triple certification system. The latest data from 2025 shows that China's annual imports of such equipment exceed 1,200 units, but 38% of enterprises still experience customs clearance delays due to documentation flaws.
According to General Administration of Customs Announcement No. 2025-7, special attention should be paid to imported filling equipment:
A Shanghai pharmaceutical company importing German filling lines in 2024 experiencedoverlooking the updated ISO 13485:2023 standard, resulting in 43 days of equipment detention at port. After professional agency intervention, resolution was achieved through:
Achievable through professional agency servicesOverall cost reduction of 18-25%:
With the implementation of 2025 Biosafety Law detailed rules, selecting agencies withspecialized qualifications for biopharmaceutical equipment importswill become enterprises' core competitiveness in ensuring production schedules and controlling compliance risks. Professional agencies can not only reduce average clearance time to 17 working days but also improve on-time delivery rates to 98.6% through comprehensive risk control systems.
? 2025. All Rights Reserved. Shanghai ICP No. 2023007705-2 PSB Record: Shanghai No.31011502009912